Amarnath Reddy Kallam received a 2025 Global Recognition Award for his visionary leadership and groundbreaking contributions ...

AbbVie (ABBV) closed at $187.12 in the latest trading session, marking a +1.23% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.06%. Elsewhere, the Dow gained 0 ...

Shares of AbbVie Inc. ABBV advanced 1.22% to $187.11 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...

AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...

AbbVie's dividends add to its attractiveness at an uncertain time, adding to robust price returns over time. Click here to ...

$56M awarded to AbbVie unit in Delaware patent fight over Botox treatment | US Botox sales reportedly grew to over $4.4 billion last year, while trade secrets lawsuit against rival continues. Already ...

AbbVie ABBV holds a leadership position in the neuroscience space, which encompasses blockbuster medications such as Botox ...

AbbVie (ABBV) faced a tough market day on July 21, 2025, as their stock price dropped by 2.33%, marking a two-day total decline of 3.42%. This significant trading volume of 9.22 billion ranked them ...

Evolus is demonstrating strong market share gains, successful new product launches, and reaffirmed 2025 revenue guidance ...

This was the stock's second consecutive day of losses.

A federal jury July 18 said Revance Therapeutics' skin medication infringed on patents for anti-wrinkle treatment Botox and owes AbbVie-owned Allergan $56 million.

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...